Citigroup Maintains Buy Rating for Syndax Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Citigroup has maintained its Buy rating for Syndax Pharmaceuticals (NASDAQ:SNDX) and increased its price target from $31.00 to $35.00. This new target price represents a 61.51% increase from the current share price. Syndax Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing combination therapies for multiple cancer indications.
July 26, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup's maintained Buy rating and increased price target for Syndax Pharmaceuticals could potentially boost investor confidence and positively impact the company's stock price in the short term.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. In this case, Citigroup's decision to maintain a Buy rating and increase the price target for Syndax Pharmaceuticals indicates a positive outlook for the company, which could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100